32 related articles for article (PubMed ID: 28792265)
1. A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements.
Bonifacio M; Scaffidi L; Miggiano MC; Facchinelli D; Tosoni L; Pezone S; Griguolo D; Ciotti G; Danini M; Bernardelli A; Bresciani R; Cavraro M; Crosera L; De March E; Dell'Eva M; Dorotea L; Frison L; Furlani L; Gianesello I; Lovato E; Marchetti E; Morelli G; Mullai R; Pizzano U; Zoletto S; Fanin R; Krampera M; Trentin L; Calistri E; Carli G; Binotto G; Tiribelli M
Blood Cancer J; 2024 Mar; 14(1):53. PubMed ID: 38531834
[No Abstract] [Full Text] [Related]
2. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Hehlmann R; Lauseker M; Saußele S; Pfirrmann M; Krause S; Kolb HJ; Neubauer A; Hossfeld DK; Nerl C; Gratwohl A; Baerlocher GM; Heim D; Brümmendorf TH; Fabarius A; Haferlach C; Schlegelberger B; Müller MC; Jeromin S; Proetel U; Kohlbrenner K; Voskanyan A; Rinaldetti S; Seifarth W; Spieß B; Balleisen L; Goebeler MC; Hänel M; Ho A; Dengler J; Falge C; Kanz L; Kremers S; Burchert A; Kneba M; Stegelmann F; Köhne CA; Lindemann HW; Waller CF; Pfreundschuh M; Spiekermann K; Berdel WE; Müller L; Edinger M; Mayer J; Beelen DW; Bentz M; Link H; Hertenstein B; Fuchs R; Wernli M; Schlegel F; Schlag R; de Wit M; Trümper L; Hebart H; Hahn M; Thomalla J; Scheid C; Schafhausen P; Verbeek W; Eckart MJ; Gassmann W; Pezzutto A; Schenk M; Brossart P; Geer T; Bildat S; Schäfer E; Hochhaus A; Hasford J
Leukemia; 2017 Nov; 31(11):2398-2406. PubMed ID: 28804124
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Goldberg SL; Cortes JE; Gambacorti-Passerini C; Hehlmann R; Khoury HJ; Michallet M; Paquette RL; Simonsson B; Zyczynski T; Foreman A; Abruzzese E; Andorsky D; Beeker A; Cony-Makhoul P; Hansen R; Lomaia E; Olavarria E; Mauro MJ
Am J Hematol; 2017 Nov; 92(11):1214-1223. PubMed ID: 28815757
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up.
Aghel N; Lipton JH; Atenafu EG; Kim DDH; Delgado DH
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):870-878.e1. PubMed ID: 28803825
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.
Aghel N; Delgado DH; Lipton JH
Vasc Health Risk Manag; 2017; 13():293-303. PubMed ID: 28831263
[TBL] [Abstract][Full Text] [Related]
6. [Dose optimization: an individualized treatment strategy for chronic myeloid leukemia].
Chen YL; Zou J; Zhang YL; Li WM
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):436-440. PubMed ID: 35680605
[No Abstract] [Full Text] [Related]
7. Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China.
Chen Y; Liu Z; Zou J; Wang D; He W; Meng L; Cheng F; Zhang Y; Li W
Haematologica; 2022 Aug; 107(8):1966-1970. PubMed ID: 35484651
[No Abstract] [Full Text] [Related]
8. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L; Akard LP
Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
10. Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.
Cayssials E; Tartarin F; Guilhot J; Sorel N; Chomel JC; Leleu X; Guilhot F
Leuk Lymphoma; 2018 Mar; 59(3):766-769. PubMed ID: 28792265
[No Abstract] [Full Text] [Related]
11. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
[TBL] [Abstract][Full Text] [Related]
12. Patients' perspectives on the definition of cure in chronic myeloid leukemia.
Flynn KE; Mauro MJ; George G; Hinman A; Baim A; Kota V; Larson RA; Lipton JH; Thompson JE; Wadleigh M; Atallah E
Leuk Res; 2019 May; 80():40-42. PubMed ID: 30955853
[No Abstract] [Full Text] [Related]
13. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
[TBL] [Abstract][Full Text] [Related]
14. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
15. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
